Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients.
Ibrahim NK, Eraky A, Eggers J, Steiert TA, Sebens S, Jünemann KP, Hendricks A, Bang C, Stanulla M, Franke A, Hamann C, Röcken C, Arnold N, Hinze L, Forster M. Ibrahim NK, et al. Among authors: stanulla m. Cancers (Basel). 2022 Feb 15;14(4):969. doi: 10.3390/cancers14040969. Cancers (Basel). 2022. PMID: 35205727 Free PMC article.
Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group.
Bartram T, Burkhardt B, Wössmann W, Seidemann K, Zimmermann M, Cario G, Lisfeld J, Ellinghaus E, Franke A, Houlston RS, Schrappe M, Reiter A, Stanulla M. Bartram T, et al. Among authors: stanulla m. Leuk Lymphoma. 2015 Mar;56(3):814-6. doi: 10.3109/10428194.2014.933479. Epub 2014 Aug 13. Leuk Lymphoma. 2015. PMID: 25005032 No abstract available.
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, Bornhauser B, Gombert M, Kratsch C, Stütz AM, Sultan M, Tchinda J, Worth CL, Amstislavskiy V, Badarinarayan N, Baruchel A, Bartram T, Basso G, Canpolat C, Cario G, Cavé H, Dakaj D, Delorenzi M, Dobay MP, Eckert C, Ellinghaus E, Eugster S, Frismantas V, Ginzel S, Haas OA, Heidenreich O, Hemmrich-Stanisak G, Hezaveh K, Höll JI, Hornhardt S, Husemann P, Kachroo P, Kratz CP, Te Kronnie G, Marovca B, Niggli F, McHardy AC, Moorman AV, Panzer-Grümayer R, Petersen BS, Raeder B, Ralser M, Rosenstiel P, Schäfer D, Schrappe M, Schreiber S, Schütte M, Stade B, Thiele R, von der Weid N, Vora A, Zaliova M, Zhang L, Zichner T, Zimmermann M, Lehrach H, Borkhardt A, Bourquin JP, Franke A, Korbel JO, Stanulla M, Yaspo ML. Fischer U, et al. Among authors: stanulla m. Nat Genet. 2015 Sep;47(9):1020-1029. doi: 10.1038/ng.3362. Epub 2015 Jul 27. Nat Genet. 2015. PMID: 26214592 Free PMC article.
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Hinze L, Möricke A, Zimmermann M, Junk S, Cario G, Dagdan E, Kratz CP, Conter V, Schrappe M, Stanulla M. Hinze L, et al. Among authors: stanulla m. Leukemia. 2017 Aug;31(8):1840-1842. doi: 10.1038/leu.2017.154. Epub 2017 May 22. Leukemia. 2017. PMID: 28529312 No abstract available.
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M. Meißner T, et al. Among authors: stanulla m. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4):a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul. Cold Spring Harb Mol Case Stud. 2017. PMID: 28679691 Free PMC article.
IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group. Stanulla M, et al. J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2. J Clin Oncol. 2018. PMID: 29498923 Free article.
RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue.
Forster M, Mark A, Egberts F, Rosati E, Rodriguez E, Stanulla M, Bauerschlag D, Schem C, Maass N, Amallraja A, Murphy KK, Prouse BR, Sulaiman RA, Young BM, Mathiak M, Hemmrich-Stanisak G, Ellinghaus D, Weidinger S, Rosenstiel P, Arnold N, Leyland-Jones B, Williams CB, Franke A, Meißner T. Forster M, et al. Among authors: stanulla m. Oncotarget. 2018 Aug 17;9(64):32362-32372. doi: 10.18632/oncotarget.25981. eCollection 2018 Aug 17. Oncotarget. 2018. PMID: 30190792 Free PMC article.
223 results